N-Propyliden-butylamin | 2038-24-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Propyliden-butylamin
• 英文别名: N-propylidenebutylamine；N-butylpropan-1-imine
• CAS: 2038-24-6
• 化学式: C₇H₁₅N
• 分子量: 113.203
• InChiKey: BXFLCAZUAUSMSQ-UHFFFAOYSA-N

物化性质

• 沸点：
  118-127 °C
• 密度：
  0.7601 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  12.4
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  N-Propyliden-butylamin 在 二氢吡啶 、 silica gel 作用下， 以 苯 为溶剂， 反应 3.0h， 以68%的产率得到N-丙基丁胺
  参考文献：
  名称：

  NAD(P)+–NAD(P)H 模型 70. 在硅胶存在下用 Hantzsch 酯还原亚胺

  摘要：

  在硅胶存在下，亚胺被 Hantzsch 酯以高产率还原成相应的胺。还原显示出高化学选择性和立体选择性。α,β-不饱和亚胺的还原以高区域选择性进行以产生烯丙胺（1,2-还原产物）。

  DOI：

  10.1246/bcsj.62.3845
• 作为产物：
  描述：

  二正丁胺 在 叔丁基过氧化氢 、 [Cu(N,N'-bis(benzimidazol-2-yl-methyl)hexane-1,6-dicarboxamide)NO₃]NO₃*2H₂O 、 1-butyl-3-methylimidazolium Tetrafluoroborate 作用下， 生成 N-Propyliden-butylamin
  参考文献：
  名称：

  N,N´-双-(苯并咪唑-2-基-甲基)-己烷-1,6-二甲酰胺配体的铜(II)配合物：离子液体中胺的合成、结构和催化氧化

  摘要：

  以N , N' -双-(苯并咪唑-2-基-甲基)-己烷-1,6-为原料合成了一种新的铜(II)配合物[Cu(L)NO 3 ]NO 3 ·2H 2 O。二甲酰胺作为配体，L = GBSA（Ahuja 和 Mathur in Spectrochim Acta Part A 83:180–186, 2011）。单晶 X 射线结构表征证实，配合物中的铜 (II) 离子具有扭曲的五配位几何形状，其中一个硝酸根阴离子作为单齿配体与铜 (II) 结合。铜(II)配合物的N 2 O 2赤道面由羰基氧原子(O1)、硝基氧原子(O3)和两个苯并咪唑氮原子(N1,N4)组成，轴向位置被氧原子( O2)的酰胺羰基。低温 EPR 研究表明四方几何形状扭曲，而阴极E 1/2值表明铜在溶液中稳定在 +2 氧化态。 TGA 数据显示了复合物的热分解模式。该配合物在离子液体中作为芳香族和脂肪族伯胺和仲胺的氧化催化剂进行了研究，[BMIM][BF

  DOI：

  10.1007/s11243-023-00566-3

文献信息

• Isomerizationi of small ring lithium dialkylamides
  作者：Martin Newcomb、William G. Williams、Robert A. Reeder

  DOI：10.1016/s0040-4039(00)85733-0

  日期：1982.1

  Lithiu N-butylcycloprpylamide () and lithium N-propylcyclobutylamide () rearrrange in ethereal solvents by nucleophilic eliminative rings fission processes; amide is highly reactive whereas amide is somewhat stable.

  通过亲核消除环裂变过程，在醚类溶剂中重排Lithiu N-丁基环丙基酰胺（）和N-丙基环丁基酰胺锂（）；酰胺具有很高的反应活性，而酰胺则具有一定的稳定性。
• N-acyloxyalkyl-carboxamides and process for their preparation
  申请人：Bayer Aktiengesellschaft

  公开号：US05599940A1

  公开（公告）日：1997-02-04

  The invention provides novel N-acyloxyalkyl-carboxamides of the general formula (I): ##STR1## in which R.sup.1 is alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkylalkyl, arylalkyl or heteroarylalkyl, each of which is optionally substituted, R.sup.2 is optionally substituted alkyl and R.sup.3 is hydrogen, halogen or optionally substituted alkyl, in the isolated and pure form, and a process for their preparation.

  该发明提供了一种新的N-酰氧基烷基-羧酰胺，其通式为(I)：##STR1## 在其中，R.sup.1是烷基，烯基，炔基，环烷基，环烷基烷基，芳基烷基或杂芳基烷基，每种基团均可选择性地被取代，R.sup.2是可选择性取代的烷基，R.sup.3是氢，卤素或可选择性取代的烷基，在分离和纯化形式下，以及它们的制备方法。
• Meth-Cohn, Otto; Westwood, Keith T., Journal of the Chemical Society. Perkin transactions I, 1984, # 6, p. 1173 - 1182
  作者：Meth-Cohn, Otto、Westwood, Keith T.

  DOI：——

  日期：——
• Schmidt,U. et al., Chemische Berichte, 1965, vol. 98, p. 3819 - 3826
  作者：Schmidt,U. et al.

  DOI：——

  日期：——
• Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria
  作者：George Jerums、Terri J. Allen、Duncan J. Campbell、Mark E. Cooper、Richard E. Gilbert、Jeremy J. Hammond、Jan Raffaele、Con Tsalamandris

  DOI：10.1016/s0272-6386(05)80003-4

  日期：2001.5

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.